(Circulation. 1995;91:2470-2477.)
© 1995 American Heart Association, Inc.
Articles |
From the Division of Cardiology, Department of Medicine, and the Department of Pathology, Loma Linda University School of Medicine, Loma Linda, Calif.
| Abstract |
|---|
|
|
|---|
Methods and Results Infrarenal AAAs were created surgically in
eight adult dogs using autologous tissue. Two types of endovascular
stents were used in this study: a plain or uncovered stent, about 14 mm
in diameter in the unconstrained configuration, and a covered stent,
coated by porous polyurethane, about 16 mm in diameter. All stents were
successfully placed on the first attempt. Aortograms revealed a mean
aneurysm diameter of 1.86±0.47 cm, an average of 70% larger than the
reference aortic lumen before stent placement. After stent placement,
aortograms showed that the aneurysmal cavity disappeared completely in
three dogs treated with a covered stent and that the aortic blood flow
into the cavity markedly reduced, with faint contrast filling the
cavity in the remaining five dogs treated with an uncovered stent. The
uncovered stent was intentionally placed across the major arterial
branches in two dogs. No acute complications were encountered at the
time of stent placement. Two dogs were killed shortly after the
procedure for immediate evaluation of the device, which was found to be
in place and patent. One dog in which a covered stent was placed was
euthanized 2
weeks later because of paraplegia
secondary to a
spinal cord infarction noted 48 hours after stent placement. Postmortem
study revealed thrombus occluding the stent lumen. The remaining five
dogs tolerated the devices well and completed 4 weeks of follow-up.
Premortem aortograms showed no residual aneurysmal cavity in four dogs
and only a small cavity in one dog that had received an uncovered
stent. All stents were fully patent with no thrombus and were either
completely or partially surfaced by neointima. Importantly,
the major arterial branches over which the uncovered stents were placed
were widely patent without obstruction by neointima.
Conclusions This study demonstrates the feasibility of percutaneous implantation of this new device and its effectiveness in the treatment of surgically created AAA in our canine model. The covered stent was able to exclude AAA immediately upon deployment and is of potential value in the emergency treatment of leaking AAAs. The uncovered stent appears to safely bridge branch arteries as well as significantly reduce the angiographic size of the aneurysm and may be useful in the elective therapy of AAAs. These results are promising, and future clinical trials to investigate the safety and efficacy of this device in humans are warranted.
Key Words: aorta aneurysm stents
| Introduction |
|---|
|
|
|---|
Interventional cardiovascular catheterization is a rapidly advancing field in which new techniques have been providing excellent results in the treatment of a number of cardiovascular diseases that formerly required surgical intervention. Endovascular stents are one of the advances in this field and have been effectively used to treat peripheral and coronary artery disease, pulmonary artery stenosis, and some types of congenital cardiac malformations.12 13
Recently, endovascular stents have been used experimentally in the treatment of aneurysms in animal models. Balko et al14 developed a polyurethane-coated expandable stent and tested it in AAA dog models. Later, Lawrence et al15 used a Dacron-wrapped Gianturco stent, Mirich et al16 tested a modified Gianturco stent covered with nylon, and Laborde et al17 tried a weft-knit Dacron tube with balloon-expandable stents in dogs for the same purpose. Although these devices could be percutaneously implanted to bridge and exclude an aneurysm, complications such as stent thrombosis and renal ischemia from placement across arterial branches occurred due to the design of the device.14 15 16 17
In an attempt to overcome these complications, we developed a self-expandable endovascular device (Schneider US Stent Division, Minneapolis, Minn) that can be implanted percutaneously and tested it by placing across surgically created AAA in dogs. The purpose of this study was to evaluate the feasibility of percutaneous placement of this device as well as its short- to intermediate-term safety and efficacy in treatment of AAA in this canine model.
| Methods |
|---|
|
|
|---|
Construction of the Device
The device was a self-expandable,
stainless steel, woven mesh
endovascular prosthesis with a guiding catheter. It was constrained by
a removable plastic sleeve; as the sleeve was withdrawn, the device
returned to its original, unconstrained size, anchoring it against the
vessel wall. Two types of stents were used in the study. One type was
covered by porous polyurethane and constructed of 24 wire filaments,
each 0.17 mm wide. It was constrained in an elongated configuration on
a unistep 12F (1F=0.33 mm) delivery system. When the device was
unconstrained, it had a diameter of 16 mm and a length of 40 to 60 mm
(Fig 1A
). The other type of stent was constructed of 48 wire
filaments, each 0.14 mm wide, without any covering over the wires. It
was constrained on a unistep 10F delivery system. When this device was
unconstrained, the diameter of the prosthesis was 14 mm and the length
was 40 to 60 mm (Fig 1B
). Three covered stents and five
uncovered
stents were used in the trial.
|
Surgical Creation of AAA Model
Each dog was sedated with 2%
sodium thiamylal; an endotracheal
tube then was placed for mechanical ventilation with 1% to 1.5%
halothane during the operation. After incising of the skin layer, a
piece of rectus abdominis fascia about 3 to 3.5 cm long by 2 to 2.5 cm
wide was taken. Upon entering the retroperitoneum, the aorta was
exposed and cross-clamped below the renal arteries and above the aortic
bifurcation. A 1-cm incision in the aorta was created, and a patch of
the fascia previously taken was sutured over the hole created in the
aorta. Two types of aneurysms were created: fusiform and saccular.
Aortic cross-clamp time ranged from 35 to 45 minutes. Prophylactic
cefazolin was given for 3 days.
Stent Implantation
Eight weeks was allowed for maturation of
the aneurysms after
surgery, in part to see if spontaneous obliteration or thrombosis of
the aneurysm would occur. The dogs then were taken back to the
catheterization laboratory, and under anesthesia an 8F sheath (USCI, CR
Bard Inc) was advanced over a guide wire into the right femoral artery.
A 6F angiographic pigtail catheter (Cordis Corp), over a 0.035-in (0.89
mm) Benson wire (Cook Co), was then advanced into the descending aorta
5 cm above the aneurysm, and an abdominal aortogram was performed by
injection of 30 mL contrast dye at 20 mL/s to document continued
patency of the surgically created AAA before stent placement. At the
end of the aortogram, the pigtail catheter and the 8F sheath were
removed from the femoral artery, leaving the Benson wire in the
descending aorta. Under fluoroscopic control, a stent that had been
premounted on a delivery catheter was passed over the Benson wire to
the desired position and deployed by pulling back the covering plastic
sleeve (Fig 2
). Immediately after stent placement, an
aortogram was performed with the same amount of contrast material and
injecting rate as the aortogram performed before stent placement to
evaluate flow through the stent and the region of the aneurysm. In two
dogs, uncovered stent was intentionally placed over the renal arteries
in one dog and over the superior and inferior mesenteric arteries in
another dog. All dogs were observed for recovery, and prophylactic
cefazolin was given for 3 days. No anticoagulants or antiplatelet drugs
were used before, during, or after the procedure.
|
Measurement of Aneurysm Size
Aneurysm size was determined
angiographically using a
computerized digital analytical system, AngioComm StatVIEW Digital
Recorder (ImageComm Systems, Inc). The measurements were independently
performed by one of the authors (C.E.R.) and a catheterization
laboratory technician (F.L.H.). Since no measurement variation was
larger than 10%, a third observer was not involved. The transverse
diameter of the contrast column was measured at its widest point, from
the outer wall of the aneurysm to the opposite wall of the aorta, or at
its widest portion of the aneurysm, whichever measurement was larger.
This was compared with a normal or reference aortic diameter defined as
the average of the "normal" aortic diameter immediately above and
below the aneurysm. Two measurements of the diameter were taken, and
the mean value was presented.
Follow-up
The first two dogs (dogs 1 and 2) were killed
shortly after
stent placement to evaluate the position and function of the stent. Dog
3 was recatheterized and euthanized 2
weeks after
stent
placement because of decubitus ulcer formation as a result of
paraplegia. The remaining five dogs underwent follow-up aortogram at
the completion of the study 4 weeks after stent placement and were
euthanized under deep sodium pentobarbital anesthesia by injection of
potassium chloride solution, with subsequent removal of the stented
segment of the aorta.
Gross and Histopathologic Study
Gross examination of each
segment of stented aorta was performed
by longitudinal opening of the aorta and stent, with inspection of the
lumen. The aneurysmal cavity also was opened and its contents examined.
Specimens were fixed in 10% buffered formalin for routine light
microscopy. Portions of the aneurysm wall and contents were submitted
for routine processing, paraffin embedding, and light microscopic study
of hematoxylin-eosinstained sections by standard methods. An attempt
was made to study the interface of the stent with the aortic intima
after removal of the embedded stent wires as carefully as possible from
the neointimal tissue, with variable success. Portions of
the stent with aortic wall were also fixed in 2% buffered
glutaraldehyde for scanning electron microscopy in dogs 4 through
8.
| Results |
|---|
|
|
|---|
Stent Implantation
The stent was successfully deployed and
placed across the aneurysm
on the first attempt in all eight dogs. Aortogram before stent
placement revealed a mean aneurysm diameter of 1.86±0.47 cm, which was
70±40% larger than the reference aortic lumen (1.09±0.08 cm)
(Table
) (Fig 3A
and Fig 4A
).
Aortogram
immediately after stent placement showed effective exclusion of flow
from the aneurysm, with reduction in the size of the angiographically
demonstrated lumen to a mean diameter of 1.16±0.35 cm, which was no
different than the reference aortic lumen (1.09±0.16 cm)
(Table
). The
aneurysmal cavity disappeared in all three dogs receiving a covered
stent (Fig 3B
), and the aortic blood flow into the aneurysmal
cavity
markedly diminished, with only faint contrast filling the cavity in all
five dogs with uncovered stents (Fig 4
, B and C). No acute
complications were observed during the placement. The average procedure
time was 30 minutes, and average fluoroscopy exposure was 3
minutes.
|
|
|
Follow-up Angiographic Study
One dog that had received a
covered stent (dog 3) developed
paraplegia secondary to spinal cord infarction 48 hours after stent
placement. An aortogram indicated that the stented section of the aorta
was completely occluded, with only very limited aortic flow from
collateral arteries distal to the stent, and this animal was euthanized
2
weeks after stent placement because of
decubitus ulcer
formation. The remaining five dogs (dogs 4 to 8) tolerated the device
well for the entire 4-week follow-up period, with no complications, and
underwent follow-up aortogram 4 weeks after stent placement
(Table
).
The diameter of the stented aortic lumen was essentially the same as
immediately after stent implantation. The aortograms showed all stents
to be patent, with vigorous flow through the stented section of the
aorta (Fig 3C
and Fig 4D
). The cavity of the
aneurysm could not be
visualized in four dogs (two with covered stents and two with uncovered
stents). Slight cavitary filling with contrast was observed in dog 5,
which had received an uncovered stent, but the angiographic size of the
aneurysmal cavity appeared to have further reduction (Fig 4D
).
Importantly, the major arterial branches bridged by the uncovered stent
were maintained with unrestricted flow through these arteries, and no
angiographic evidence of the residual aneurysm was revealed (Fig
5
).
|
Gross Examination
No migration of the stent was noted in the
dogs. The two dogs that
were killed shortly after stent placement (dogs 1 and 2) showed a fully
deployed, patent stent across the site of the aneurysm, with no clot.
Dog 3, which had angiographic evidence of thrombosis as described
above, was found to have thrombus filling the entire lumen of the stent
as well as the cavity of the aneurysm. In the remaining five dogs, all
stents were patent, with no significant clot in the lumen. The stents
were either totally or partially covered with neointima,
and the saccular aneurysms were essentially completely filled with clot
(Fig 6A
), while the fusiform aneurysms showed adherence of
the stent to the aortic wall with contraction of the aortic (aneurysm)
diameter but without significant thrombosis. In dog 5, which had
angiographic evidence of a small residual aneurysm, the stent wires
were covered by neointima around the edges of the aneurysm
and the cavity was mostly filled with clot. In two dogs in which the
uncovered stents had been intentionally placed across the renal
arteries and superior and inferior mesenteric arteries, the patency of
those arteries was maintained without obstruction by
neointima (Fig 6B
).
|
Light and Scanning Electron Microscopy
The covered stents
showed fibroblastic and histiocytic permeation
of the coating fabric by light microscopy, with patchy chronic
inflammation and variable endothelialization of the surface (Fig
7A
). A fibroblastic reaction was focally present in the
intima beneath the stent. Some areas showed fibroplasia of the intimal
surface as well, with a microlayer of adherent thrombus. One dog that
received a covered stent (dog 4) showed focal penetration of a stent
wire into the aortic media, with associated chronic inflammation. This
was uncommon, however, and most of the stent wires appeared to rest on
the aortic intima, with or without a thin layer of intervening intimal
fibrous reaction. The dog with thrombosis of a covered stent (dog 3)
showed focal necrosis of the inner aortic wall, apparently secondary to
the thrombosis. Histological study of tissue reaction associated with
the uncovered stent was considerably more difficult, as the
neointimal tissue was very thin and easily disrupted by
removing the stent wires before sectioning. However, we were able to
demonstrate a mild histiocytic and giant cell reaction to the wires,
with a thin overlying layer of neointima composed largely
of myofibroblastic-type cells, and little reaction in the underlying
aorta. The clot in the aneurysms typically showed peripheral
organization (Fig 7B
).
|
Scanning electron microscopy
showed the neointimal surface
to be covered by cells with the appearance of fibroblasts, with
variably sized islands of endothelial cells partially covering the
fibroblasts (Fig 8
, A and B). The endothelial cells in some
areas appeared to have migrated onto the neointimal surface
through porelike spaces between the wires.
|
| Discussion |
|---|
|
|
|---|
Further refinement and simplification of surgical techniques in AAA repair seem unlikely at present.19 However, nonsurgical ablation by means of implantation of a specially designed device to bridge AAA has been tested in animal experimental studies and appears promising. This alternative is expected to result in less morbidity and mortality than surgical repair and has the potential to significantly reduce the cost of treatment of AAA.
Previous Studies
Several intraluminal devices have been
tested previously in the
treatment of AAA in animal models. Balko et al14
used a polyurethane graft with a Nitinol and/or stainless steel frame
to bridge the artificial aneurysm with a 15F catheter. The aneurysms
were successfully excluded, and the patency and position of the
device were confirmed shortly after the device implantation.
However, no follow-up study was performed. Important disadvantages
associated with this device were the potential for premature expansion
inside the catheter due to its material (Nitinol), which required
constant cold saline irrigation, and the large size of the catheter
required for placement, limiting its application.
Lawrence et al15 developed an expandable Gianturco stent covered with Dacron and tested it in normal aorta of dogs. However, because of the nonexpandable nature of its Dacron covering as well as its tendency to wrinkle, there was concern regarding its long-term promotion of thrombosis and fibrogenesis, with possible eventual stenosis or thrombosis. In addition, side branch arteries were occluded by the Dacron covering.
To overcome the disadvantages of the device, Mirich et al16 percutaneously placed a modified Gianturco stent in six dogs with surgically created AAA. The modified stent was covered by porous nylon material to allow stretching and to maintain patency of the side arterial branches where covered by the stent. It had a fully expanded size of 11 to 12 mm with a 12F delivery catheter. One of the dogs had incomplete stent expansion due to a defect of the device, with subsequent cephalad stent migration and death as a result of occlusion of the renal arteries. In the remaining dogs, the aneurysm was successfully sealed off. There was no evidence of device migration or luminal narrowing. Microscopic examination revealed neointimal coating of the fabric strands across side branch arteries and evidence of renal ischemia in one dog, indicating that these vessels might eventually be occluded.
More recently, Laborde et al17 developed a weft-knit Dacron tube with balloon-expandable stents that were placed across artificial AAAs in eight dogs. Initial success in excluding AAA was achieved in all the dogs. However, two had early occlusion caused by torsion of the device as a result of defective folding inside the delivery sheath. At follow-up, the remaining dogs had patent Dacron grafts, but four showed evidence of kinking due to shrinkage of the artificial aneurysm. Histopathologic study demonstrated endothelialization that was complete on the stents and partial in the artificial aneurysms.
Present Study
We used two types of new endovascular devices
in the treatment of
AAA in a dog model. Except for one dog with early stent occlusion, we
did not encounter any complications in the placement or use of this
device. The two types of this device have somewhat different features
and therefore may have potentially different clinical applications. The
covered stent would appear likely to be most useful in the emergency
treatment of ruptured or acutely expanding AAAs, since in our study it
appeared to exclude aneurysms immediately upon placement and therefore
might be able to stop bleeding from a leaking or acutely expanding
aneurysm. However, because of its fabric coating, it could not be
allowed to bridge the entrance of any major arterial branch because it
would also interrupt blood flow through that artery. Fortunately, most
human AAAs occur below the renal arteries, so it would not be necessary
to bridge those arteries with a covered stent. Exclusion of spinal
arteries did not appear to be a problem in our dogs; signs of spinal
cord ischemia were not observed except in the one dog whose stent
thrombosed shortly after placement. However, only three dogs were
treated with the covered stent, and more animal experimental studies
are certainly required after further refinement and improvement in
device design and technique.
The uncovered stent has not been reported to be used in experimental animals, but its features suggest it to be potentially useful in the elective therapy of stable AAAs. This device was able to significantly reduce the angiographic size of most aneurysms, providing a framework for neointimal growth while also maintaining the patency of branch arteries. In the two animals in which these stents were placed across major arterial branches, those branches were widely patent, with unrestricted blood flow at 4 weeks after stent placement. This unique aspect of the uncovered stent holds promise for the long-term treatment of AAA, although longer follow-up is needed. The effect of the uncovered stents on aneurysm size was in some cases less dramatic than that of the covered stent; however, it was able to either obliterate or substantially reduce the size of the aneurysm in all cases by the end of the 4-week follow-up period. This is an important achievement because a strong correlation has been demonstrated between aneurysm size and the likelihood of rupture.2 3 6 10
It appears likely that the mechanism of closure of the saccular aneurysms by the uncovered stent is by reduction of blood flow in the aneurysm cavity secondary to the shear forces introduced by the wires that cross the aneurysm opening. This is suggested by only faint contrast filling the aneurysmal cavity immediately after placement of the stent. The mechanism of shrinkage of the fusiform aneurysms is less clear. However, the almost immediate reduction in the angiographically demonstrated diameter of the aorta in the region of the aneurysm in two of the three dogs with fusiform aneurysms suggests that the shear forces introduced by the stent wires may redirect blood flow back toward the lumen and away from the dilated aortic walls, allowing for healing and contraction of the dilated aorta. The one case in which the diameter was slightly greater immediately after stent placement appears to be due to placement of a relatively large stent in a fairly small dog, which resulted in some initial stretching of the aorta. This case, however, went on to show normalization of the aortic diameter with 4 weeks of follow-up. The obliteration of the aneurysms in all cases appears to be due to the presence of the stent and not to spontaneous thrombosis, as angiography demonstrated immediate changes in the effective size of the aorta after stent placement. Furthermore, the aortogram before stent placement showed that the size of the aneurysms appeared to be larger rather than reduction from the original created size in the initial 8 weeks after aneurysm creation, a period designed to serve as a control for any possible spontaneous healing, regression, or thrombosis of the aneurysms.
Placement of the device was feasible and straightforward and appears to be safe. We did not encounter any difficulty in positioning or deploying the stent. However, several considerations must be kept in mind. One must be certain that the stent is in the correct position before withdrawing the covering sheath for deployment since it is not retrievable once deployed. Care also must be taken not to bridge any major arteries with a covered stent, otherwise kidney or other visceral damage will almost certainly ensue.
Thrombosis and Endothelialization
Minimal thrombosis and
rapid endothelialization are critical
issues for the success of stent placement.20 All stents in
our study showed at least partial neointimal
endothelialization at the end of 4 weeks and generally minimal thrombus
on the aortic luminal aspect of the stent. Palmaz et
al21 22 23 24 have
demonstrated the absence of thrombosis over a
long time period after aortic graft placement. This would suggest that
anticoagulation is not necessary after aortic stent placement because
of the vigorous blood flow. However, Schatz20 pointed out
that metallic stents, regardless of design and configuration, have an
inherent thrombogenic effect without adequate anticoagulation. In our
study, one stent was completely occluded by thrombus, which might be
prevented by administering anticoagulants, and similar stent thrombosis
has been reported by others.12 16 17
Thus, anticoagulation
may be important for stent placement even in the aorta. Further studies
are warranted to clarify this important issue.
Although infection and colonization of the stented area did not occur in our study, this potential complication must be given serious consideration. Prophylactic administration of antibiotics, as used here, is recommended for a short period after stent placement. Once a stent is completely covered with neointima, the likelihood of infection as well as thrombosis may be minimized, so that long-term antibiotic therapy probably is not indicated.
Limitations
The surgically created aneurysms in the animal
model are not
necessarily comparable in configuration to the most common AAAs in
humans, particularly with respect to the opening of the aneurysmal
cavity, which was proportionally smaller than in human AAAs. It is
uncertain whether neointimal surfacing of an uncovered
stent would be as rapid and complete in these larger aneurysms as it
was in our study. Further studies are indicated in this regard.
The present study was based on short-term and immediate follow-up after stent placement in a relatively small sample size. Although the data are encouraging, longer follow-up and a larger sample size are needed to establish both the long-term efficacy and safety of this procedure.
Conclusions
Our study serves to document the feasibility of
percutaneous
placement of an endovascular stent in the treatment of AAA in an animal
model. Short-term follow-up suggests this to be a relatively safe and
effective method for nonsurgical treatment of AAA in the dog and
deserving of serious consideration for use in humans when further
refinements in technique are accomplished. If proven safe and effective
for humans as well, it has the potential for substantially reducing the
morbidity and mortality associated with AAA.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received July 11, 1994; revision received October 31, 1994; accepted November 26, 1994.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. D. Moffatt-Bruce and R. S. Mitchell Endovascular Therapy for the Treatment of Thoracic Aortic Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1299 - 1308. [Full Text] |
||||
![]() |
S. D. Moffatt and R. S. Mitchell Endovascular Stent Management of Thoracic Aneurysms and Dissections Card. Surg. Adult, January 1, 2003; 2(2003): 1191 - 1204. [Full Text] |
||||
![]() |
C. E. Ruiz, H. P. Zhang, A. I. Butt, and P. Whittaker Percutaneous Treatment of Abdominal Aortic Aneurysm in a Swine Model : Understanding the Behavior of Aortic Aneurysm Closure Through a Serial Histopathological Analysis Circulation, October 7, 1997; 96(7): 2438 - 2448. [Abstract] [Full Text] |
||||
![]() |
U. Blum, G. Voshage, J. Lammer, F. Beyersdorf, D. Tollner, G. Kretschmer, G. Spillner, P. Polterauer, G. Nagel, T. Holzenbein, et al. Endoluminal Stent-Grafts for Infrarenal Abdominal Aortic Aneurysms N. Engl. J. Med., January 2, 1997; 336(1): 13 - 20. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |